• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

34
13
11
10
4

COUNTRY

11
2
1
1
1

CATEGORIES

  • 112
  • 87
  • 38
  • 37
  • 30
  • 26
  • 12
  • 11
  • 9
  • 5
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL…

PRICE

12
167
274
358

PUBLISHED

2
18
81
358

PRODUCT TYPE

222
126
2
1

Search "Alzheimer Disease Therapy Area Pipeline Report" returned 358 results.

PRODUCT TITLE
Aricept (Alzheimer's disease) - Analysis and Forecasts to 2022 Aricept (Alzheimer's disease) - Analysis and Forecasts to 2022 - Product Thumbnail Image

Aricept (Alzheimer's disease) - Analysis and Forecasts to 2022

Aricept (Alzheimer’s disease) – Analysis and Forecasts to 2022 Summary GlobalData’s pharmaceuticals report, “Aricept (Alzheimer’s disease) – Analysis and Forecasts to 2022” provides Aricept global...

April 2012
FROM
AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022 AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022 - Product Thumbnail Image

AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022

AAB-001 (bapineuzumab) (Alzheimer’s disease) – Analysis and Forecasts to 2022 Summary GlobalData’s pharmaceuticals report, “AAB-001 (bapineuzumab) (Alzheimer’s disease) – Analysis and Forecasts to...

April 2012
FROM
Gammagard Liquid (Alzheimer's disease) - Analysis and Forecasts to 2022 Gammagard Liquid (Alzheimer's disease) - Analysis and Forecasts to 2022 - Product Thumbnail Image

Gammagard Liquid (Alzheimer's disease) - Analysis and Forecasts to 2022

Gammagard Liquid (Alzheimer’s disease) – Analysis and Forecasts to 2022 Summary GlobalData’s pharmaceuticals report, “Gammagard Liquid (Alzheimer’s disease) – Analysis and Forecasts to 2022” provides...

April 2012
FROM
Namenda (Alzheimer's disease) - Analysis and Forecasts to 2022 Namenda (Alzheimer's disease) - Analysis and Forecasts to 2022 - Product Thumbnail Image

Namenda (Alzheimer's disease) - Analysis and Forecasts to 2022

Namenda (Alzheimer’s disease) – Analysis and Forecasts to 2022 Summary GlobalData’s pharmaceuticals report, “Namenda (Alzheimer’s disease) – Analysis and Forecasts to 2022” provides Namenda global...

April 2012
FROM
LY2062430 (Alzheimer's disease) - Analysis and Forecasts to 2022 LY2062430 (Alzheimer's disease) - Analysis and Forecasts to 2022 - Product Thumbnail Image

LY2062430 (Alzheimer's disease) - Analysis and Forecasts to 2022

LY2062430 (Alzheimer’s disease) – Analysis and Forecasts to 2022 Summary GlobalData’s pharmaceuticals report, “LY2062430 (Alzheimer’s disease) – Analysis and Forecasts to 2022” provides LY2062430...

April 2012
FROM
Gene Therapy - Technologies, Markets and Companies Gene Therapy - Technologies, Markets and Companies - Product Thumbnail Image

Gene Therapy - Technologies, Markets and Companies

Gene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state. Genes...

June 2015
FROM

Alzheimer's Drugs Market, 2012 - 2017

Alzheimer's disease is a neurodegenerative disease of the brain which leads to loss of memory and cognitive functions With ageing world population, the number of patients suffering from Alzheimer's...

May 2013
FROM
Nitric Oxide - Therapeutics, Markets and Companies Nitric Oxide - Therapeutics, Markets and Companies - Product Thumbnail Image

Nitric Oxide - Therapeutics, Markets and Companies

This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based...

June 2015
FROM

Proteome Sciences Plc (PRM) - Product Pipeline Analysis, 2013 Update

Summary Proteome Sciences Plc (Proteome Sciences) is a protein biomarker company. The company delivers content for personalized medicine in different areas such as biomarker assays, biomarker services,...

July 2013
FROM

Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies

This report provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection,...

February 2011
FROM

Proteome Sciences Plc (PRM) - Product Pipeline Analysis

Summary Proteome Sciences Plc (Proteome Sciences) is a biotechnology company that delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology...

November 2012
FROM

Amarantus Bioscience Holdings, Inc. (AMBS) - Product Pipeline Analysis, 2013 Update

Summary Amarantus Bioscience Holdings, Inc. (Amarantus BioScience) is a biotechnology company. The company discovers and develops treatments and diagnostics for diseases associated with neurodegeneration...

August 2013
FROM
The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007 The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007 - Product Thumbnail Image

The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007

With a market size of US$14 5 billion in 2005 and an anticipated value of US$16 5 billion in 2006, the neurodegenerative market represents a valuable, fast-growing opportunity in the pharma/biotech...

January 2007
FROM

PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - China Drug Forecast and...

July 2013
FROM

The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

“The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis ” The report provides in-depth analysis of unmet...

December 2009
FROM

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease

GBI Research’s report “Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for...

May 2013
FROM
Alzheimer's Disease Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011 Alzheimer's Disease Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011 - Product Thumbnail Image

Alzheimer's Disease Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011

This report presents a comprehensive review of autoantibodies, and pipeline vaccines and therapeutic antibodies, in Alzheimer's disease (AD) Currently, drug treatments for AD are dominated by cholinesterase...

March 2011
FROM

PharmaPoint: Alzheimer's Disease - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - France Drug Forecast...

July 2013
FROM

Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features Innovative Stem Cell and Gene Therapy Applications

GBI Research, the leading business intelligence provider, has released its latest research, “Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features Innovative...

June 2012
FROM

Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies

“Early Stage Drug Development in Disease Segments – Innovation Focuses on Stem Cell Therapies and Gene Therapies”, provides an in-depth analysis of the unmet needs, drivers and barriers that affect...

February 2011
FROM
Loading Indicator

Our Clients

Intel Corporation Autodesk, Inc. Hewlett-Packard Company Ahlstrom Corporation SAP SE 3M Company Samsung Group Ltd.